Share This Author
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
CABG remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year.
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
This poster presents a probabilistic procedure called “Cardialysis BV, Rotterdam, The Netherlands”, which aims to establish a baseline for the use of this procedure in the treatment of chronic kidney disease.
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical…
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluted stents than with bare-metal stents, and both drug-elution stents were associated with a marked reduction in target-lesion revascularization.
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials.
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.
The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.
Bivalirudin for patients with acute coronary syndromes.
In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin.
Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature.